AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ARTV · NASDAQ · Biotechnology

Artiva Biotherapeutics

Develops cryopreserved allogeneic NK-cell candidates for autoimmune diseases and cancer.

$11.14

After-hours close+0.06 (+0.54%)

At close$11.08(−7.20%)

Something off on this page? Send us feedback.

Profile

Artiva Biotherapeutics, Inc.ARTVHealth Care

Develops AlloNK, an off-the-shelf, cryopreserved allogeneic NK-cell therapy candidate for B-cell-driven autoimmune diseases. Its pipeline also includes CAR-NK programs for solid and hematologic cancers, while it has no approved products for commercial sale.

Develops AlloNK (AB-101), an off-the-shelf, cryopreserved allogeneic NK-cell therapy candidate for B-cell-driven autoimmune diseases. The company has prioritized refractory rheumatoid arthritis as its lead indication, while AlloNK is being evaluated in ongoing trials across autoimmune diseases. Its pipeline also retains CAR-NK candidates for solid and hematologic cancers.

Originated as a GC Cell spinout, with an exclusive, royalty-bearing license to specified NK-cell intellectual property and technology in the world excluding Asia, Australia, and New Zealand. With no products approved for commercial sale, the business depends on clinical development, regulatory progress, manufacturing, and commercialization of its candidates within that licensed territory.

Company facts

CEOFred Aslan, M.D.

ListedJul 19, 2024

ExchangeNASDAQ

HeadquartersSan Diego, CA

CountryUnited States

Employees106

CIK0001817241

ISINUS04317A1079

Key statistics

Market cap$542.2M

EPS (ttm)−$3.31

P/E (ttm)−3.35

ROE-53.9%

P/B1.26

P/S0.00

Dividend yield—

Beta2.06vs XLV 1.33

Year to date +162% · Average volume (30d) 329.7K

Analysts

Price target, next 12 months$37.50+238.1%Median of 4 analysts · vs the Aug 28 close

ConsensusBuy4 of 4 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $11.09

High$40.00+260.7%

Median$37.50+238.1%

Low$35.00+215.6%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
May 11, 2026	Wedbush	Reiterate	Outperform	$18	$40
May 8, 2026	H.C. Wainwright	Target			$35

Earnings

EPS

Estimate−$0.54

ReportedDue Nov 11, 2026

Revenue

Estimate—

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.63	−$0.63	−0.8%	—	—	—	−2.68%
Aug 5, 2026Q2 FY26	−$0.64	−$0.63	+1.6%	—	—	—	−0.09%
May 8, 2026Q1 FY26	−$0.88	−$0.95	−8.0%	—	—	—	−2.66%
Mar 10, 2026Q4 FY25	−$0.87	−$0.84	+3.4%	—	—	—	+17.27%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$666.0K	$0
Operating income	−$22.2M	−$22.8M	−$22.9M	−$21.9M	−$24.4M	−$26.9M
Net income	−$20.3M	−$21.3M	−$21.5M	−$20.8M	−$23.5M	−$25.0M
Diluted EPS	−$0.83	−$0.87	−$0.88	−$0.85	−$0.95	−$0.63
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY23 $33.5M · FY24 $251.0K · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $349.4M · Total debt $9.8M · Total assets $368.6M · Shareholders' equity $347.5M

Dividends

No dividends on record.

Ownership

Institutions 34.43%16.83M sharesInsiders 41.45%20.27M sharesOther 24.12%11.79M shares

Shares outstanding 48.89M · Float 19.45M · 39.8% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Ra Capital Management, L.P. · director, 10 percent owner:	17.33M	35.45%	Form 4	Jul 31, 2026
GC Corp. · 10 percent owner	6.00M	12.27%	Form 4	May 28, 2026
Viking Global Investors LP	2.60M	5.40%	13G	May 18, 2026
5Am Venture Management, LLC	2.35M	4.81%	13F	May 15, 2026
VR Adviser, LLC	1.61M	3.29%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 18, 2026	Subhashis Banerjee	officer: Chief Medical Officer	−429	$12.00
Jul 29, 2026	Ra Capital Management, L.P.	director, 10 percent owner:	+20,824	$9.99
Jul 31, 2026	Ra Capital Management, L.P.	director, 10 percent owner:	+24,944	$9.93
Jul 24, 2026	Ra Capital Management, L.P.	director, 10 percent owner:	+41,319	$9.99
Jul 13, 2026	Ra Capital Management, L.P.	director, 10 percent owner:	+13,074	$8.94